GlassScriptPhysician profile
Charles B Baggett
NPI 1336357060
$5,552.08
in general payments reported to CMS, 2019-2025
36 companies · $96.72 in 2025
The $96.72 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $1,729 · 2021: $629 · 2022: $867 · 2023: $567 · 2024: $839 · 2025: $96.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,384.29 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,339.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $365.19 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $329.14 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $263.26 | 2019-2025 | Camzyos, Eliquis |
| Atricure, INC. | $184.62 | 2023 | |
| Cvrx, INC. | $155.56 | 2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $151.90 | 2019-2022 | |
| Osprey Medical INC | $117.81 | 2019-2021 | |
| Boston Scientific Corporation | $92.79 | 2022-2024 | Ams 700 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.22 | 2019-2025 | Lifevest |
| W. L. Gore & Associates, INC. | $84.75 | 2020-2021 | |
| Abbott Laboratories | $82.97 | 2023 | Aveir |
| Lexicon Pharmaceuticals, INC. | $79.78 | 2023-2024 | Inpefa |
| Livanova USA, INC. | $77.58 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $73.83 | 2019-2024 | Kengreal, Cleviprex |
| Esperion Therapeutics, INC. | $72.51 | 2021-2024 | Nexletol |
| Medtronic, INC. | $70.62 | 2021-2022 | |
| Cordis US Corp. | $68.18 | 2022-2024 | Infiniti, Rain Sheath |
| Novo Nordisk INC | $57.26 | 2024-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.11 | 2019-2020 | |
| Amgen INC. | $46.33 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $44.68 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $40.49 | 2019-2020 | |
| Biotronik INC. | $31.49 | 2021 | |
| Impulse Dynamics (USA) INC. | $25.40 | 2023 | Optimizer |
| Xeris Pharmaceuticals, INC. | $22.83 | 2022 | |
| Terumo Medical Corporation | $19.63 | 2019 | |
| Bardy Diagnostics, INC. | $17.00 | 2019-2020 | |
| Akcea Therapeutics, INC. | $16.63 | 2021 | |
| Merck Sharp & Dohme LLC | $16.55 | 2024 | Verquvo |
| Nuwellis, INC. | $16.10 | 2019 | |
| Baxter Healthcare | $15.70 | 2025 | |
| Varian Medical Systems, INC. | $15.54 | 2020 | |
| Vital Connect, INC | $14.78 | 2024 | Vitalpatch Rtm |
| Glaxosmithkline, LLC. | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Baggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.